Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 12/20 | 0.80 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | CDK2 | P24941 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22095314 | 0.94 | AURKA (0.76) | AURKAKDM5BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22095046 | 0.92 | AURKA (0.81) | AURKAKDM5BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22095059 | 0.92 | AURKA (0.67) | AURKAKDM5BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22095290 | 0.91 | MEN1 (0.74) | AURKAKDM5BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22095286 | 0.89 | KDM5B (0.95) | AURKAKDM5BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22095087 | 0.89 | AURKA (0.84) | AURKAMEN1KMT2AMAPTTP53 | |
| SCHEMBL22095548 | 0.89 | MAPT (0.81) | AURKAKDM5BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22095268 | 0.87 | AURKA (1.00) | AURKAKDM5BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22095213 | 0.87 | AURKA (0.61) | AURKAKDM5BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28498019 | 0.87 | KDM5B (1.00) | AURKAKDM5BMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548875-B2 | Inhibitor compounds for male contraception | UNIVERSITY OF WASHINGTON (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2021-10-28 | — | — | US | disclosed |
| WO-2020123855-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | ALDH1A1, ALDH3A1, ALDH16A1 | AURKA 3852/4885KDM5B 363/4885MEN1 3040/4885 |
| US-11548875-B2 | Inhibitor compounds for male contraception | ALDH1A1, ALDH3A1, ALDH16A1 | AURKA 3852/4885KDM5B 363/4885MEN1 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.